-
Mashup Score: 5Man in twenties went for neck adjustment with chiropractor and now has locked-in syndrome - 17 day(s) ago
Jonathan Buckelew, 34, suffered a severe stroke and subsequently ended up with locked-in syndrome after having his neck adjusted by a chiropractor.
Source: www.ladbible.comCategories: General Medicine NewsTweet
-
Mashup Score: 162AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - 21 day(s) ago
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome…
Source: news.abbvie.comCategories: General Medicine NewsTweet-
Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. https://t.co/DlDzq32mn0
-
-
Mashup Score: 162AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - 21 day(s) ago
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome…
Source: news.abbvie.comCategories: General Medicine NewsTweet-
Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. https://t.co/DlDzq32mn0
-
-
Mashup Score: 162AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - 21 day(s) ago
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome…
Source: news.abbvie.comCategories: General Medicine NewsTweet-
Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. https://t.co/DlDzq32mn0
-
-
Mashup Score: 160AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - 22 day(s) ago
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome…
Source: news.abbvie.comCategories: General Medicine NewsTweet-
Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. https://t.co/DlDzq32mn0
-
-
Mashup Score: 40ASCO® 2025 Insights: All-Oral Regimen of Decitabine-Cedazuridine + Venetoclax in Newly Diagnosed AML Ineligible for Intensive Induction Chemo - 27 day(s) ago
A video from Amer Zeidan (as part of 2025 ASCO® Annual Meeting Insights Hub), posted on Jun 6, 2025.
Source: www.vumedi.comCategories: General Medicine NewsTweet-
What a pleasure to present & usher a new era in #AMLsm with total oral therapy through #ASCERTAIN-V study at @ASCO25 All-Oral Regimen of Decitabine-Cedazuridine + Venetoclax in Newly Diagnosed AML Ineligible for Intensive Induction Chemo https://t.co/oc5H8KRG7r
-
-
Mashup Score: 298th Annual Live Medical Crossfire®: Hematologic Malignancies - 28 day(s) ago
July 20, 2024
Source: www.gotoper.comCategories: General Medicine NewsTweet-
8th Annual Live Medical Crossfire®: Hematologic Malignancies 📅Date: July 20, 2024 📍Location: Conrad New York (In-person only) 📋agenda & register: https://t.co/qgcjrn9Djz or https://t.co/HvLrKpmAML 💸FREE registration when using my last name (Zeidan) as a code during checkout
-
-
Mashup Score: 298th Annual Live Medical Crossfire®: Hematologic Malignancies - 1 month(s) ago
July 20, 2024
Source: www.gotoper.comCategories: General Medicine NewsTweet-
8th Annual Live Medical Crossfire®: Hematologic Malignancies 📅Date: July 20, 2024 📍Location: Conrad New York (In-person only) 📋agenda & register: https://t.co/qgcjrn9Djz or https://t.co/HvLrKpmAML 💸FREE registration when using my last name (Zeidan) as a code during checkout
-
-
Mashup Score: 29Post-EHA 2025 MDS Highlights | VJHemOnc - 1 month(s) ago
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
Join us for this free virtual highlights of #MDSsm abstracts from #ASCO2025 & #EHA2025 on July 1st, 2025 9am-11am eastern USA time delivered by the authors themselves and debated by an expert panel @VJHemOnc register for free at https://t.co/mHa6U1jDno
-
-
Mashup Score: 11
Artificial intelligence (AI) has the potential to transform cancer therapeutic decision-making by improving diagnostics and personalizing treatments. This review explores the current and future imp…
Source: ai.nejm.orgCategories: General Medicine NewsTweet-
RT @UsuarezMD: The Use of Artificial Intelligence for Cancer Therapeutic Decision-Making | NEJM AI https://t.co/94WB6p4ilE
-
Beyond me how anyone would let a chiropractor aggressively manipulate their neck. https://t.co/xVtjOc5uje